TCR2 Therapeutics Inc. Profile Avatar - Palmy Investing

TCR2 Therapeutics Inc.

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (T…

Biotechnology
US, Cambridge [HQ]
Revenue Breakdowns

Segment Analysis Beta

The financial segments are sourced from the SEC' 10-K statement.

Revenue By Top Segments

TCR2 Therapeutics Inc. can't present it's sankey chart.

Historical Revenue By Segment

Last 3Y, in million USD

TCR2 Therapeutics Inc. can't present revenue by segment

End of TCRR's Analysis
CIK: 1750019 CUSIP: 87808K106 ISIN: US87808K1060 LEI: - UEI: -
Secondary Listings
TCRR has no secondary listings inside our databases.